Title

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Intervention/Treatment

    azficel-T ...
  • Study Participants

    13
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM in subjects with maxillary lesions who were treated in a previous study (IT-G-002, no NCT identification number)
Study Started
Jan 31
2006
Primary Completion
Apr 30
2008
Study Completion
Jul 31
2008
Results Posted
Aug 15
2013
Estimate
Last Update
Mar 23
2021

Biological Autologous Human Fibroblasts (azficel-T)

Collection of biopsy from palate Papillary priming procedure Seven injection treatments to target sites Performance of study assessments (investigator and subject)

  • Other names: LAVIV

Active Experimental

Criteria

Inclusion Criteria:

Subject must be 18-70 years of age
Subject was treated in IT-G-002 (no NCT identification number)
Subject has maxillary interproximal recession defects
Natural teeth must be present on both sides of each area to be treated
Negative pregnancy test and use of acceptable birth control (females of childbearing age)

Exclusion Criteria:

Subjects who participated in other clinical trials within 30 days prior to enrollment
Interproximal spaces including root grooves or furcations must not be involved
Subjects with poor oral hygiene
Subjects with a systemic condition, which would preclude periodontal treatment
Subjects with acute infectious lesions in the treatment areas
Subjects with open interproximal contact at study sites
Subjects who must receive prophylactic antibiotics before dental procedures
Subjects on chronic antibiotic or steroidal therapy
Subjects with interproximal probing depths > 3 mm around study lesions
Subjects who smoke
Subjects taking medications associated with the development of drug induced gingival hyperplasia
Subjects with radiographic evidence of pathology
Subjects with tooth mobility exceeding a score of 1
Subjects with parafunctional habits and not wearing bite guard
Subjects with interproximal spaces associated with teeth without an adequate zone of keratinized tissue
Subjects where the etiology of the interproximal papillary recession has not been controlled
Subjects who have received a crown or pontic on one or both teeth involved in the interproximal space to be treated

Summary

Autologous Fibroblasts

All Events

Event Type Organ System Event Term Autologous Fibroblasts

Number of Responders Based on the Average Investigator Evaluation of Change From Baseline for All Treated Areas on the Global Ordinal Rating Scale (GORS)

A patient was considered a responder in this outcome measure if the average Investigator's GORS score for all treatment areas was greater than 0. On the GORS, a score of -2 (much worsening from baseline) was the worst and +2 (great improvement from baseline) was the best.

Autologous Fibroblasts

10.0
participants

Number of Responders Based on the Average Patient Evaluation of Change From Baseline for All Treated Areas on the Global Ordinal Rating Scale (GORS)

A patient was considered a responder in this outcome measure if the average patient's GORS score for all treatment areas was greater than 0. On the GORS, a score of -2 (much worsening from baseline) was the worst and +2 (great improvement from baseline) was the best.

Autologous Fibroblasts

9.0
participants

Age, Categorical

Race (NIH/OMB)

Sex: Female, Male

Overall Study

Autologous Fibroblasts

Drop/Withdrawal Reasons

Autologous Fibroblasts